NO20050149L - Fremgangmate ved behandling av iskemisk reperfusjonsskade ved anvendelse av adenosinreseptor-antagonister - Google Patents
Fremgangmate ved behandling av iskemisk reperfusjonsskade ved anvendelse av adenosinreseptor-antagonisterInfo
- Publication number
- NO20050149L NO20050149L NO20050149A NO20050149A NO20050149L NO 20050149 L NO20050149 L NO 20050149L NO 20050149 A NO20050149 A NO 20050149A NO 20050149 A NO20050149 A NO 20050149A NO 20050149 L NO20050149 L NO 20050149L
- Authority
- NO
- Norway
- Prior art keywords
- reperfusion injury
- receptor antagonists
- adenosine receptor
- progress
- ischemic reperfusion
- Prior art date
Links
- 206010063837 Reperfusion injury Diseases 0.000 title abstract 3
- 229940121359 adenosine receptor antagonist Drugs 0.000 title abstract 2
- 230000000302 ischemic effect Effects 0.000 title abstract 2
- 239000000296 purinergic P1 receptor antagonist Substances 0.000 title abstract 2
- 101150078577 Adora2b gene Proteins 0.000 abstract 1
- 241000124008 Mammalia Species 0.000 abstract 1
- 208000012947 ischemia reperfusion injury Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
- C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Cardiology (AREA)
- Immunology (AREA)
- Heart & Thoracic Surgery (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- General Physics & Mathematics (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Analytical Chemistry (AREA)
- Hospice & Palliative Care (AREA)
- Pulmonology (AREA)
- Diabetes (AREA)
- Surgery (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US38868002P | 2002-06-12 | 2002-06-12 | |
| PCT/US2003/018695 WO2003105666A2 (fr) | 2002-06-12 | 2003-06-12 | Procede de traitement des lesions consecutives a la perfusion ischemique au moyen des antagonistes de recepteurs d'adenosine |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NO20050149D0 NO20050149D0 (no) | 2005-01-11 |
| NO20050149L true NO20050149L (no) | 2005-03-11 |
Family
ID=29736516
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20050149A NO20050149L (no) | 2002-06-12 | 2005-01-11 | Fremgangmate ved behandling av iskemisk reperfusjonsskade ved anvendelse av adenosinreseptor-antagonister |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US20050203065A1 (fr) |
| EP (1) | EP1513848A4 (fr) |
| JP (1) | JP2005533054A (fr) |
| CN (1) | CN1671716A (fr) |
| AU (1) | AU2003236509A1 (fr) |
| BR (1) | BR0312137A (fr) |
| CA (1) | CA2489179A1 (fr) |
| EA (1) | EA200500005A1 (fr) |
| IS (1) | IS7592A (fr) |
| MX (1) | MXPA04012629A (fr) |
| NO (1) | NO20050149L (fr) |
| NZ (1) | NZ537444A (fr) |
| PL (1) | PL374498A1 (fr) |
| RS (1) | RS107404A (fr) |
| SG (1) | SG131115A1 (fr) |
| UA (1) | UA84404C2 (fr) |
| WO (1) | WO2003105666A2 (fr) |
| ZA (1) | ZA200500254B (fr) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE411058T1 (de) | 2001-10-25 | 2008-10-15 | Univ Emory | Katheter für modifizierte perfusion |
| US20070160645A1 (en) * | 2001-10-25 | 2007-07-12 | Jakob Vinten-Johansen | PostConditioning System And Method For The Reduction Of Ischemic-Reperfusion Injury In The Heart And Other Organs |
| CA2592142A1 (fr) * | 2004-12-22 | 2006-06-29 | Emory University | Appoints therapeutiques destines a ameliorer les effets de protection des organes du post-conditionnement |
| US20090221649A1 (en) * | 2005-03-24 | 2009-09-03 | Bayer Healthcare Ag | Use of substituted 2-thio-3,5-dicyano-4-phenyl-6-aminopyridines for the treatment of reperfusion injury and reperfusion damage |
| ES2270715B1 (es) | 2005-07-29 | 2008-04-01 | Laboratorios Almirall S.A. | Nuevos derivados de pirazina. |
| TW201402124A (zh) * | 2005-08-19 | 2014-01-16 | Array Biopharma Inc | 作為類鐸受體（ｔｏｌｌ-ｌｉｋｅ ｒｅｃｅｐｔｏｒ）調節劑之８-經取代苯并氮雜呯 |
| ES2274712B1 (es) | 2005-10-06 | 2008-03-01 | Laboratorios Almirall S.A. | Nuevos derivados imidazopiridina. |
| DE102006046410A1 (de) * | 2006-09-20 | 2008-03-27 | Eberhard-Karls-Universität Tübingen Universitätsklinikum | Arzneimittel zur Prophylaxe oder Behandlung oder Diagnostik von ischämischen Krankheiten |
| WO2009152458A1 (fr) * | 2008-06-13 | 2009-12-17 | Biogen Idec Ma Inc. | Formulation liquide appropriée pour une perfusion renfermant un antagoniste des récepteurs de l’adénosine destinée à traiter une insuffisance cardiaque ou une insuffisance rénale |
| AR085942A1 (es) * | 2011-04-07 | 2013-11-06 | Gilead Sciences Inc | Uso de receptor de aadenosina para tratar la insuficiencia cardiaca y la arritmia en pacientes posinfarto de miocardio |
| TWI566772B (zh) * | 2011-04-12 | 2017-01-21 | 資生堂股份有限公司 | 美白劑及黑色素生成抑制劑 |
| CN102274232B (zh) * | 2011-06-22 | 2013-03-27 | 南京理工大学 | 腺苷受体a1拮抗剂在制备药物中的应用 |
| US10531655B2 (en) | 2011-12-02 | 2020-01-14 | The Regents Of The University Of California | Reperfusion protection solution and uses thereof |
| JP2016516708A (ja) * | 2013-03-14 | 2016-06-09 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | ビシクロ［２．２．２］酸のｇｐｒ１２０モジュレーター |
| US11351149B2 (en) | 2020-09-03 | 2022-06-07 | Pfizer Inc. | Nitrile-containing antiviral compounds |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8510758D0 (en) * | 1985-04-27 | 1985-06-05 | Wellcome Found | Compounds |
| JPH06102662B2 (ja) * | 1989-09-01 | 1994-12-14 | 協和醗酵工業株式会社 | キサンチン誘導体 |
| US5443836A (en) * | 1993-03-15 | 1995-08-22 | Gensia, Inc. | Methods for protecting tissues and organs from ischemic damage |
| US5736528A (en) * | 1993-10-28 | 1998-04-07 | University Of Florida Research Foundation, Inc. | N6 -(epoxynorborn-2-yl) adenosines as A1 adenosine receptor agonists |
| WO1995011681A1 (fr) * | 1993-10-29 | 1995-05-04 | Merck & Co., Inc. | Antagonistes du recepteur de l'adenosine humaine |
| US5733916A (en) * | 1995-03-24 | 1998-03-31 | The Trustees Of The University Of Pennsylvania | Prevention and treatment of ischemia-reperfusion and endotoxin-related injury using adenosine and purino receptor antagonists |
| US6117878A (en) * | 1998-02-24 | 2000-09-12 | University Of Virginia | 8-phenyl- or 8-cycloalkyl xanthine antagonists of A2B human adenosine receptors |
| US6303619B1 (en) * | 1998-03-12 | 2001-10-16 | University Of Virginia | Meta-substituted acidic 8-phenylxanthine antagonists of A3 human adenosine receptors |
| US6187780B1 (en) * | 1998-04-16 | 2001-02-13 | Boehringer Ingelheim Pharma Kg | Assymetrically substituted xanthine derivatives having adenosine A1 antagonistic activity |
| DE19816857A1 (de) * | 1998-04-16 | 1999-10-21 | Boehringer Ingelheim Pharma | Neue unsymmetrisch substituierte Xanthin-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
| SK6622002A3 (en) * | 1999-11-12 | 2003-02-04 | Biogen Inc | Adenosine receptor antagonists and methods of making and using the same |
| PT1230243E (pt) * | 1999-11-12 | 2009-06-12 | Biogen Idec Inc | Policicloalquilpurinas como antagonistas dos receptores da adenosina |
| UA80258C2 (en) * | 2001-09-06 | 2007-09-10 | Biogen Inc | Methods of treating pulmonary disease |
-
2003
- 2003-06-12 AU AU2003236509A patent/AU2003236509A1/en not_active Abandoned
- 2003-06-12 CN CNA038174332A patent/CN1671716A/zh active Pending
- 2003-06-12 EA EA200500005A patent/EA200500005A1/ru unknown
- 2003-06-12 SG SG200701729-6A patent/SG131115A1/en unknown
- 2003-06-12 EP EP03737066A patent/EP1513848A4/fr not_active Withdrawn
- 2003-06-12 JP JP2004512582A patent/JP2005533054A/ja active Pending
- 2003-06-12 PL PL03374498A patent/PL374498A1/xx not_active Application Discontinuation
- 2003-06-12 RS YUP-1074/04A patent/RS107404A/sr unknown
- 2003-06-12 UA UAA200500247A patent/UA84404C2/ru unknown
- 2003-06-12 NZ NZ537444A patent/NZ537444A/en not_active IP Right Cessation
- 2003-06-12 MX MXPA04012629A patent/MXPA04012629A/es not_active Application Discontinuation
- 2003-06-12 CA CA002489179A patent/CA2489179A1/fr not_active Abandoned
- 2003-06-12 BR BR0312137-2A patent/BR0312137A/pt not_active IP Right Cessation
- 2003-06-12 WO PCT/US2003/018695 patent/WO2003105666A2/fr not_active Ceased
-
2004
- 2004-12-06 US US11/006,022 patent/US20050203065A1/en not_active Abandoned
- 2004-12-10 IS IS7592A patent/IS7592A/is unknown
-
2005
- 2005-01-11 ZA ZA200500254A patent/ZA200500254B/en unknown
- 2005-01-11 NO NO20050149A patent/NO20050149L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| SG131115A1 (en) | 2007-04-26 |
| EA200500005A1 (ru) | 2005-06-30 |
| AU2003236509A1 (en) | 2003-12-31 |
| BR0312137A (pt) | 2005-04-05 |
| PL374498A1 (en) | 2005-10-31 |
| WO2003105666A3 (fr) | 2004-09-16 |
| MXPA04012629A (es) | 2005-10-18 |
| NO20050149D0 (no) | 2005-01-11 |
| NZ537444A (en) | 2006-09-29 |
| EP1513848A2 (fr) | 2005-03-16 |
| WO2003105666A2 (fr) | 2003-12-24 |
| CA2489179A1 (fr) | 2003-12-24 |
| UA84404C2 (ru) | 2008-10-27 |
| US20050203065A1 (en) | 2005-09-15 |
| JP2005533054A (ja) | 2005-11-04 |
| CN1671716A (zh) | 2005-09-21 |
| IS7592A (is) | 2004-12-10 |
| RS107404A (sr) | 2007-02-05 |
| ZA200500254B (en) | 2006-04-26 |
| EP1513848A4 (fr) | 2005-11-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20050149L (no) | Fremgangmate ved behandling av iskemisk reperfusjonsskade ved anvendelse av adenosinreseptor-antagonister | |
| NO20065230L (no) | Kondenserte pyridinderivater anvendelige som A28 adenosinreseptorantagonister | |
| DK1171137T3 (da) | Anvendelse af triacetyluridin til behandling af mitochondriale lidelser | |
| TW200509910A (en) | Substituted pyrazole derivatives and related compounds as bradykinin B1 receptor antagonists | |
| NO20073140L (no) | Pyrrolopyraziner og pyralopyraziner som er nyttige som inhibitorer av proteinkinaser | |
| DK2140881T3 (da) | Fremgangsmåder til behandling af iskæmisk eller hæmoragisk læsion i centralnervesystemet ved anvendelse af anti-alpha-4-integrin-antagonister | |
| WO2007002635A3 (fr) | Antagonistes cycliques a liaison c du recepteur p2y1, utiles pour traiter des etats pathologiques thrombotiques | |
| UA86591C2 (ru) | Пирролодигидроизохинолины как ингибиторы pde10, фармацевтическая композиция на их основе | |
| WO2005000298A3 (fr) | Inhibiteurs de p-38 | |
| ATE548389T1 (de) | Therapeutische und diagnostische verfahren und zusammensetzungen zum targeting von 4ig-b7-h3 und dem entsprechenden nk-zellen-rezeptor | |
| SMP200600024B (it) | 2,6-Biseteroaril-4-amminopirimidine come antagonisti del recettore dell'adenosina | |
| NO20010446L (no) | Substituert anilidforbindelser og metoder | |
| NO20073628L (no) | Pyridoner som er nyttige som inhibitorer av kinaser | |
| NO20061952L (no) | Pyrimidin-2-aminderivater og deres anvendelse som A2B-adenosinreseptorantagonister | |
| CY1110464T1 (el) | Παραγωγα πυραζολοπυριδινης ως αναστολεις του βητα-αδρενεργικου υποδοχεα της κινασης1 | |
| NO20070502L (no) | Azaindoler nyttige som inhibitorer av proteinkinaser | |
| ECSP055762A (es) | 4-amino-1-(piridilmetil)piperidina sustituida como antagonistas de receptores muscarinicos | |
| DK1480627T3 (da) | Fremgangsmåder til mindskelse af angiogenese | |
| DE602007012313D1 (de) | Als a2b-adenosinrezeptorantagonisten geeignete 5-phenyl-6-pyridin-4-yl-1,3-dihydro-2h-imidazoä4,5-büpyridin-2-onderivate | |
| EA200900010A1 (ru) | Замещенные 8-[6-амино-3-пиридил]ксантины | |
| NO20061981L (no) | Arylindenopyridiner og arylindenopyridiner og deres anvendelse som adenosin A2A reseptoragonist | |
| WO2006071775A3 (fr) | Composes utiles pour l'antagonisme du recepteur b1 de la bradykinine | |
| DE60318694D1 (de) | 4-(pyrrolopyrimidin-6-yl)benzolsulfonamidderivate | |
| Röthlisberger et al. | Incorporation of a minimal nucleotide into DNA | |
| NO20002408L (no) | 5-HT1F antagonister |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |